Tag: Cell Signaling and Communication

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors

Purpose BMS-986299 is a first-in-class, NOD-, LRR-, and pyrin-domain containing-3 (NLRP3) inflammasome agonist enhancing adaptive immune and T-cell memory responses. Materials and methods This was a phase-I (NCT03444753) study that assessed the safety and tolerability of intra-tumoral BMS-986299 monotherapy (part 1A) and in combination (part 1B) with nivolumab, and ipilimumab in advanced solid tumors. Reported… Continue reading Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors

Clinical Trials Are Testing Ways to Prevent Breast Cancer

Higher screening rates along with treatment advances have reduced breast cancer deaths by 42% in recent decades. Still, it remains the second deadliest cancer among women in the United States, with over 40,000 expected to die of the disease last year. And for the almost 4 million women living with breast cancer, the physical and mental… Continue reading Clinical Trials Are Testing Ways to Prevent Breast Cancer

SABCS Session Provides Clinical Implications of New Data and Practical Takeaways

The 2024 San Antonio Breast Cancer Symposium (SABCS) concluded with a “View from the Trenches” panel discussing the clinical implications of key findings presented during the symposium. Bringing medical, surgical, and radiation oncology specialists together with a breast cancer thriver turned patient advocate, the conversation explored how these latest findings might alter how clinicians navigate… Continue reading SABCS Session Provides Clinical Implications of New Data and Practical Takeaways

FDA Approvals in Oncology: October-December 2024 

To help our readers keep track of the cancer therapies approved by the U.S. Food and Drug Administration (FDA), understand their impact for patients, and put them in context of the current therapeutic landscape, Cancer Research Catalyst provides a quarterly review of the latest approvals in oncology from the FDA.    The FDA had a busy 2024, issuing… Continue reading FDA Approvals in Oncology: October-December 2024 

Editors’ Picks, December 2024: Immunosuppression in the Lung, New Mathematical Models, and More

As we ring in 2025, Cancer Research Catalyst wishes you a very Happy New Year! May your 2025 be full of love, connection, and inspiration. As always, we love to keep you connected with inspiring cancer research by sharing this month’s editors’ picks from the 10 American Association for Cancer Research (AACR) journals. December’s holiday… Continue reading Editors’ Picks, December 2024: Immunosuppression in the Lung, New Mathematical Models, and More

Optogenetic Control of Dopamine Receptor 2 Reveals a Novel Aspect of Dopaminergic Neurotransmission in Motor Function

Dopaminergic neurotransmission plays a crucial role in motor function through the coordination of dopamine receptor (DRD) subtypes, such as DRD1 and DRD2, thus the functional imbalance of these receptors can lead to Parkinson’s disease. However, due to the complexity of dopaminergic circuits in the brain, it is limited to investigating the individual functions of each… Continue reading Optogenetic Control of Dopamine Receptor 2 Reveals a Novel Aspect of Dopaminergic Neurotransmission in Motor Function